Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The eukaryotic 80S ribosome A-site in the peptidyl transferase center (PTC) is a fundamental component of the cellular machinery responsible for protein synthesis [1]. This site is located within the large (60S) ribosomal subunit and is the location where the 3' end of the aminoacyl-tRNA is positioned to undergo peptide bond formation with the growing polypeptide chain [3]. While historically viewed as a target for antibiotics in prokaryotes, the eukaryotic A-site is increasingly recognized as a therapeutic target for nonsense suppression therapy in genetic disorders [5]. Small molecules, such as certain aminoglycosides and their derivatives like ELX-02, bind to this region to induce translational read-through of premature stop codons, potentially restoring the production of full-length proteins in diseases like cystic fibrosis [2]. Furthermore, the PTC is a target for various ribotoxic stress-inducing agents and translation inhibitors used in oncology research. Selective targeting of the eukaryotic ribosome remains a challenge due to the potential for systemic toxicity and interference with mitochondrial protein synthesis [1]. Understanding the structural nuances of the eukaryotic A-site is essential for developing selective modulators that minimize toxicity while restoring the production of essential proteins.
Drugs targeting this site typically modulate the fidelity of the decoding process or inhibit peptide bond formation. In nonsense suppression therapy, molecules bind the A-site to induce a conformational change that allows near-cognate tRNA to pair with a premature stop codon, facilitating the synthesis of full-length proteins [1, 2].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic 80S ribosome aminoacyl-tRNA site (A-site) in the peptidyl transferase center (80S ribosome A-site).